| IR | drop of voltage across a resistor produced by a current; ileal resection; immune response; immunizat... |
|---|---|
| YFI | yellow fever immunization |
| αHBe | Antibody against Hepatitis Be Antigen |
| αHBs | Antibody against Hepatitis B surface Antigen |
| IgMαHBc | IgM Antibody against Hepatitis B core Antigen |
| influenza type a | A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection. Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine. (27 Sep 1997) |
|---|---|
| influenza vaccine | A special vaccine which provides immunity to infection by a variety of Influenza viruses. The vaccine is updated annually due to the constant introduction of new viral strains. Flu vaccination programs are common in the elderly population and any other groups who are at increased risk of viral infection. (27 Sep 1997) |
| influenza virus | <organism, virology> Member of the Orthomyxoviridae that causes influenza in humans. There are three types of influenza virus. Each type of virus has a stable nucleoprotein group antigen common to all strains of the type, but distinct from that of the other type; each also has a mosaic of surface antigens (haemagglutinin and neuraminidase) which characterise the strains and which are subject to variations of two kinds: 1) a rather continual drift that occurs independently within the haemagglutinin and neuraminidase antigens; 2) after a period of years, a sudden shift (notably in type A virus of human origin) to a different haemagglutinin or neuraminidase antigen. The sudden major shifts are the basis of subdivisions of type A virus of human origin. Type A causes the world wide epidemics (pandemics) of influenza and can infect other mammals and birds. Type B only affects humans. Type C causes only a mild infection. Types A and B virus evolve continuously, resulting in changes in the antigenicity of their spike proteins, preventing the development of prolonged immunity to infection. The spike proteins, external haemagglutinin and neuraminidase have been studied as models of membrane glycoproteins. Strain notations indicate type, geographic origin, year of isolation, and, in the case of type A strains, the characterizing subtypes of haemagglutinin and neuraminidase antigens (e.g., A/Hong Kong/1/68 (H3 N2); B/Hong Kong/5/72). (08 Mar 2000) |
| influenza viruses | Virus's of the family Orthomyxoviridae which cause influenza and influenza-like infections of humans and other animals; virus's included are influenza virus types A and B of the genus Influenzavirus, causing, respectively, influenza A and B, and influenza virus type C, which probably belongs to a separate genus and causes influenza C. (05 Mar 2000) |
| influenza virus vaccines | Influenza virus grown in embryonated eggs and inactivated, usually by the addition of formalin; both whole virus and subunit preparations containing haemagglutinins and neuraminidase are used; because of the marked and progressive antigenic variation of the influenza viruses, the strains included are regularly changed following various outbreaks of influenza in order to include most recently isolated epidemic strains of both type A influenza and type B influenza. (05 Mar 2000) |
| endemic influenza | Influenza, usually of a less severe type, occurring with some degree of regularity during the winter season, especially in the larger cities of the world. Synonym: influenza nostras. (05 Mar 2000) |
| equine influenza | <veterinary, virology> A highly contagious upper respiratory infection of horses and other equids caused by equine strains of influenza virus type A. It is characterised by fever and respiratory signs similar to but more severe than those of equine rhinopneumonitis; oedema of the lower trunk and limbs (epizootic cellulitis) may occur; the disease is frequently fatal when secondary bacterial pneumonia intervenes. (05 Mar 2000) |
| active immunization | The production of active immunity. (05 Mar 2000) |
| anthrax immunization | A series of six shots over six months and booster shots annually, the anthrax vaccine now in use in the USA was first developed in the 1950s and approved by the Food and Drug Administration for general use in 1970. It is produced by the Michigan Biologic Products Institute of Michigan's Department of Health and is given routinely to veterinarians and others working with livestock. In December, 1997 it was announced that all US military would receive the vaccine, as do the military in the UK and Russia, the reason being concern that anthrax might be used in biologic warfare. (12 Dec 1998) |
| german measles immunization | The standard MMR vaccine is given to prevent measles, mumps and rubella (German measles). The MMR vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or MMR vaccination prior to entrance. Most children should receive MMR vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the MMR vaccine. Pregnant women should wait until after delivery before being immunised with MMR. People with HIV or AIDS should normally receive MMR vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination. (12 Dec 1998) |
| passive immunization | The production of passive immunity. (05 Mar 2000) |
| measles immunization | The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination. (12 Dec 1998) |
| chickenpox immunization | This vaccine prevents the common disease known as chickenpox (varicella zoster). While chickenpox is often considered a trivial illness, it can cause significant lost time on the job and in school and have serious complications including ear infections, pneumonia, and infection of the rash with bacteria, inflammation of the brain (encephalitis) leading to difficulty with balance and coordination (cerebellar ataxia), damaged nerves (palsies), and Reye's syndrome, a potentially fatal complication. The vaccination requires only one shot given at about a year of age. If an older person has not had chickenpox, the shot may be given at any time. There have been few significant reactions to the chickenpox vaccine. All children, except those with a compromised immune system, should have the vaccination. (12 Dec 1998) |
| rubella immunization | The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination. (12 Dec 1998) |
| mumps immunization | The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination. (12 Dec 1998) |